invasive fungal infection
The incidence of invasive and mucosal fungal infections has increased over the past few decades, particularly among immunocompromised patients. 1, 2 Invasive fungal infections (IFI) are important causes of morbidity and mortality in patients undergoing allogeneic hematopoietic SCT. Up to now, amphotericin B is the standard treatment for IFI. 1, 3, 4 Amphotericin B is a broad-spectrum, effective antifungal agent, but its use is associated with nephrotoxicity and infusion-related side effects. 5, 6 To date, no efficient salvage therapy has been available if amphotericin B fails to clear the infection, or if the patient is intolerant to amphotericin B.
The echinocandins are novel antifungal agents that have consistently demonstrated activity against a variety of fungi. They act by inhibiting the synthesis of 1,3-b-D glucan, which is an important component of the fungal cell wall. 4, [7] [8] [9] Caspofungin (CAS) is the first antifungal agent in this new class. CAS has proven to be effective and well tolerated in the treatment of infections caused by Aspergillus spp, Candida albicans and non-C. albicans spp. [10] [11] [12] [13] [14] CAS (70 mg loading dose followed by 50 mg daily) was used in an open-label, noncomparative, multicenter salvage trial of patients (n ¼ 90) with invasive aspergillosis.
14, 15 These patients had been unresponsive to 7 days of prior standard therapy or had been unable to tolerate therapy. A complete or partial response to CAS therapy was seen in 44.6% of this severely ill patient population. Randomized, double-blind, multicenter studies of adults with invasive candidiasis found that CAS was as effective as amphotericin B in C. albicans and non-C. albicans infections, but much better tolerated. 16 In other randomized, double-blind clinical trials, the safety and tolerability of CAS was comparable to fluconazole and superior to that of amphotericin B.
Following allogeneic SCT, patients receive immunosuppressive therapy for graft-versus-host disease (GvHD). IFI can be common under such conditions. 17, 18 These patients frequently suffer from multidrug side effects and induced toxicity, often due to antifungal therapy. Owing to these tolerability issues, first-line therapy often has to be interrupted due to renal insufficiency or liver toxicity. We hypothesized that CAS would be an appropriate secondline therapy, given its efficacy and tolerability. The present study reports the results of CAS monotherapy in 31 patients who did not respond or were not able to tolerate standard antifungal therapy.
Patients and methods

Patient population
Patients described in this retrospective analysis of cases had undergone allogeneic SCT following a myeloablative conditioning regimen. All patients treated with CAS as a second-line antifungal therapy were retrospectively included in this series of cases. Thus, an individual therapeutic approach formed the base of this treatment. Although immediately before the transplant procedure no evidence of fungal disease was noted, 15 patients had documented IFI in their clinical history. According to the EORTC criteria, IFI were classified as: proven (eight of 15), probable (five of 15), and possible (two of 15). Among patients with proven infections, the infecting pathogens were identified as Candida krusei (n ¼ 4), C. tropicalis (n ¼ 1), Candida sp (n ¼ 1), and Aspergillus fumigatus (n ¼ 2). In all, 16 patients had fever of unknown origin, defined according to CDC criteria. We retrospectively evaluated the outcome of these patients for response and tolerance of second-line antifungal treatment. Complete responses were defined by the resolution of all clinical signs and symptoms and more than 90% of the lesions due to invasive mycosis that were visible on radiology. Clinical stabilization was defined as either clinical improvement and greater than 50% improvement in findings on radiology or clinical improvement and recovery of neutrophils during treatment. Failure of therapy was defined by worsening disease.
Antifungal and immunosuppressive prophylaxis and treatment
All patients received total gut decontamination using ciprofloxacin (750 mg, twice daily) and metronidazole (400 mg, three times daily). As antifungal prophylaxis, 20 of 31 patients received oral fluconazole (200 mg daily), while 11 patients with IFI in their history received oral itraconazole (200 mg, twice daily).
First-line antifungal treatment was initiated in 15 of 31 patients for IFI and in 16 of 31 for FUO. First-line antifungal therapy failed in 21 patients: 10 patients had persisting fever, seven showed radiological progression of infection, three had persisting positive blood cultures, and one had a positive galactomannan test. For the reason of safety, CAS was introduced as a second-line antifungal treatment in four patients after an increase of C-reactive protein (CRP) was documented.
In all, 20 patients did not tolerate first-line antifungal therapy because of renal insufficiency; one patient also experienced simultaneous moderate liver failure. First-line intravenous antifungal therapies consisted of amphotericin B (average 50 mg/day, range 10-90 mg/day) (n ¼ 17), liposomal amphotericin B (1 mg/kg body weight/day) (n ¼ 5), itraconazole 200 mg/day (n ¼ 4), fluconazole 400 mg/day (n ¼ 3), or voriconazole loading dose 6 mg/kg body weight twice daily followed by 3 mg/kg body weight twice daily (n ¼ 2).
CAS was initiated as second-line antifungal monotherapy. After a loading dose of 70 mg, 26 of 31 patients were treated by a daily dose of 50 mg daily for 7 to 71 days. The remaining patients received 35 mg/day due to increased bilirubin levels. All patients received adjuvant immunosuppressive therapy for acute (n ¼ 25) or chronic (n ¼ 6) GvHD: cyclosporin A (CSA) (n ¼ 23), high-dose prednisolone (n ¼ 13), or monoclonal antibodies (n ¼ 4). One patient received additional immunosuppression with a CD34 þ selected peripheral stem cell graft.
Safety evaluation
Laboratory evaluations were carried out to monitor drug safety. Serum levels of CRP, creatinine, potassium, bilirubin, gamma GT, and GPT serum levels were taken initially, at maximal and minimal points during, and at the end of CAS therapy. The Mann-Whitney test was used to compare independent values.
In total, 28 matched paired controls were identified for 14 of the first 17 patients treated. Two matched controls were identified for each patient. Patients were matched for disease, disease state, date of transplantation (712 months), conditioning regimen, gender, degree of acute GvHD, age, relation (matched unrelated vs identical sibling or alternative family donors), and HLA identity. Laboratory values were compared at the same day post transplant both at the beginning and at the end of CAS therapy. Serum levels of creatinine, total protein, gamma GT, GPT, AP, bilirubin, and CRP were analyzed. All of the patients in the matched paired analysis received CSA.
Results
A total of 31 patients who had undergone allogeneic SCT following a myeloablative conditioning regimen were individually treated with CAS as second-line antifungal therapy. Cases were retrospectively documented. Clinical characteristics of these patients are shown in Table 1 . In all, 24 patients were neutropenic (mean ANC o100/ml; range 0-300/ml). The median duration of neutropenia was 14 days (range 0-109 days) prior to the beginning of CAS therapy. Table 2) . Clinical stabilization was defined as resolution of signs and symptoms of IFI analogous in time to neutrophil recovery. Over half of all patients with IFI (53%), five with proven, two with probable, and one with possible infection, achieved complete resolution or clinical stabilization. The majority of patients with fever of unknown origin (94%) also experienced complete resolution or stabilization (Table 2) .
Safety and tolerability
None of the patients in this study exhibited CNS disease or severe liver failure (Child Pugh Score X9). In five patients with existing mild liver failure, the daily dose of CAS was reduced to 35 mg/day for 2 to 61 days. Significant decreases in CRP and creatinine were noted after administration of CAS. The median GPT levels increased from 6.8l to 18.6 U/l following administration of CAS, although this was still within the normal range. Serum ANC levels increased from o100/ml to a median of 1400/ml by the end of CAS therapy. CAS was generally well tolerated. No infusion-related side effects were noted. A total of 28 matched paired controls were identified for 14 of the first 17 patients treated. All patients were on CSA. Laboratory values for the 14 patients and 28 matched controls were obtained at the same number of days post transplant at the beginning and end of CAS therapy ( Table 3 ). The only significant difference between groups at the end of CAS therapy was an increase in bilirubin levels (P ¼ 0.01). Among CAS-treated patients, mean bilirubin levels increased from 3.4 mg/dl (s.d. ¼ 4.384) to 6.8 mg/dl (s.d. ¼ 7.512); in the control group, mean bilirubin levels of 2.3 mg/dl (s.d. ¼ 4.792) and 2.2 mg/dl (s.d. ¼ 3.792) before and after treatment, respectively. Bilirubin levels returned to baseline 14 days after termination of CAS therapy.
Discussion
Failure of antifungal therapy is an important cause of morbidity and mortality following SCT. The therapeutic options are very limited for patients who do not respond to Table 2 Clinical outcome using second-line CAS therapy in 15 patients with IFI and 16 patients with fever of unknown origin
All patients were recalcitrant to or intolerant of first-line antifungal therapies, which included amphotericin B (AmB), liposomal amphotericin B (AmB Lipo), voriconazole, fluconazole, and itraconazole. In addition to the favorable safety profile, 74% of patients who received CAS therapy experienced complete resolution or clinical stabilization of infection. This was notable, given that 10 patients had failed first-line therapy, six patients were intolerant to first-line therapy, and 15 patients both failed and were intolerant to first-line therapy. Another important finding was that patients who were severely neutropenic prior to initiation of CAS therapy experienced both resolution of infection and neutrophil recovery while receiving CAS. Patients with allogeneic SCT tend to have reduced T-cell function even after ANC reconstitution. This means that CAS may be an effective therapy in these immunocompromised patients. The efficacy of CAS prior to neutrophil recovery has in fact been observed previously in patients with aspergillosis. 14 GvHD is coincident with IFI in many patients. This condition, combined with the need for immunosuppressive therapies such as CSA, favors progression of IFI. The ideal antifungal agent for these patients would be effective in the context of neutropenia, GvHD, and immunosuppressive regimens. It has been suggested that there may be the potential for interactions between CAS and CSA. 11, 15 We found that CAS and CSA could be administered concomitantly without any major side effects.
In conclusion, we found that CAS was an effective second-line therapy for IFI following allogeneic SCT. CAS was associated with less toxicity than amphotericin B, the current standard of therapy. In addition, we found no significant interaction in patients treated with CAS and CSA and that their use together was well tolerated.
